Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study

doi:10.12998/wjcc.v9.i30.9059

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 30

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4151)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

230

WORD

105

HTML

2429

Figures (1-3)

153

Tables (1-2)

145

Sum=3062

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

328

Download

761

Sum=1089

Oct 26, 2021 (publication date) through May 1, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Clin Cases. Oct 26, 2021; 9(30): 9059-9069
Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.9059

Table 2 Univariate and multivariate analysis of factors associated with the development of postembolization syndrome

Factors	Univariate analysis			Multivariate analysis
Factors	OR	95%CI	P value	OR	95%CI	P value
Size > 3 cm	4.2	1.672-10.553	0.002^a	3.661	1.395-9.605	0.008^a
Dexamethasone	0.242	0.105-0.559	0.001^a	0.271	0.114-0.647	0.003^a

^aP < 0.05.

Citation: Sainamthip P, Kongphanich C, Prasongsook N, Chirapongsathorn S. Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study. World J Clin Cases 2021; 9(30): 9059-9069
URL: https://www.wjgnet.com/2307-8960/full/v9/i30/9059.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i30.9059